Biomea Fusion (BMEA) announced the presentation of ... and potential as a combination therapy with GLP-1-based medicines. ATTD 2025 Conference Highlights: First Large-Scale Analysis of C-Peptide ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

PG-102 is ProGen’s Fc-fusion protein conjugated GLP-1/GLP-2 dual agonist. delivered via the RaniPill capsule. ProGen recently announced preliminary results of the repeat-dose portion of its ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

More people are eating more protein because it not only tastes great, but it is part of an important lifestyle. And when it ...

The company is also developing BMF-650 which is a next-generation GLP-1 receptor agonist for diabetes and obesity. Biomea Fusion, Inc. (NASDAQ:BMEA) expects Phase 2b data for COVALENT-111 and ...

RT-114 combines ProGen's FC fusion protein conjugated GLP-1/GLP-2 dual agonist PG-102 with the RaniPill. The rationale behind this strategic partnership is to combine a potential best-in-class GLP ...

America’s colleges and universities enrich everyone in ways that aren’t often acknowledged. It’s high time to remind Americans of them.

RT-114 combines ProGen's FC fusion protein conjugated GLP-1/GLP-2 dual agonist PG-102 with the RaniPill. The rationale behind this strategic partnership is to combine a potential best in class GLP ...

Victoza, produced by Novo Nordisk, holds FDA approval for regulating blood sugar levels among individuals diagnosed with type ...

Fusion foods and multi-cuisine cooking is on the rise ... In stark contrast to number 4, the weight-loss trend is back and it’s bigger than ever. The rise of GLP-1 drugs and myriad new diets, has ...